Subtype
Colorectal Adenocarcinoma
CI-CAN-00005002Explore in graph →
114 active trials1 approved drugs16 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005002Explore in graph →
Clinical trials
367 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (54)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03087071 | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | active not recruiting | Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03599752 | Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases | active not recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 2 | Jul 16, 2026 | clinicaltrials |
| NCT06840977 | COLON ERDERLY LOW DOSE(CELOW) | recruiting | — | 51 | Matteo ClavarezzaOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07695519 | SCARLET - Italian proSpeCtionAl obseRvationaL multicEntre Study on Treatment for recTal pT1 Cancer(SCARLET) | not yet recruiting | — | 196 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07691489 | A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer | not yet recruiting | Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07691632 | Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05308446 | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | active not recruiting | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT06314958 | Stage II/III Colorectal Cancer Recurrence(CENSURE) | recruiting | — | 400 | City of Hope Medical CenterOTHER | 3 | Jul 7, 2026 | clinicaltrials |
| NCT06342401 | Early Onset Colorectal Cancer Detection(ENCODE) | recruiting | — | 400 | City of Hope Medical CenterOTHER | 4 | Jul 7, 2026 | clinicaltrials |
| NCT06342440 | Early Detection of Advanced Adenomas and Colorectal Cancer(AACRC) | recruiting | — | 2,000 | City of Hope Medical CenterOTHER | 5 | Jul 7, 2026 | clinicaltrials |
| NCT05710406 | Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer | active not recruiting | Phase 2 / Phase 3 | 1 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | terminated | Phase 2 | 17 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07549399 | SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC(CRITⅡ) | recruiting | Phase 3 | 204 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07595874 | Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3(NEST3) | recruiting | Phase 2 | 100 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02945566 | Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?(STAR-TREC) | active not recruiting | Phase 2 / Phase 3 | 380 | University of BirminghamOTHER | 5 | Jun 29, 2026 | clinicaltrials |
| NCT06780787 | FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery | recruiting | Phase 2 | 26 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673393 | Improving Prognostication in Colon Cancer(MARBLE) | not yet recruiting | — | 400 | Universitaire Ziekenhuizen KU LeuvenOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07669220 | A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)(STAR) | recruiting | Phase 2 | 76 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT00079274 | Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer | completed | Phase 3 | 3,397 | National Cancer Institute (NCI)NIH | 3 | Jun 23, 2026 | clinicaltrials |
| NCT04457284 | Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06971848 | Evaluation of Skin Tests in Biotherapy Allergies(ETCABIO) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02600949 | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | enrolling by invitation | Phase 1 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07596290 | Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC(RADICAL) | not yet recruiting | Phase 2 / Phase 3 | 342 | Beijing Friendship HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT06843434 | A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04616183 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04729322 | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04017650 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06637462 | A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer | recruiting | N/A | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07319104 | Liquid Biopsy in Early Colorectal Lesions(FECCO-BioBank) | not yet recruiting | — | 1,000 | University Hospital, MontpellierOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT00002968 | Edrecolomab in Treating Patients With Stage II Colon Cancer | completed | Phase 3 | 2,100 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04739072 | Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study | recruiting | — | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03095781 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 47 | Emory UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03594630 | Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer | recruiting | Early Phase 1 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07589517 | Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer(DUO-CRC-NK-111) | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05672524 | A Study of Tucatinib and Trastuzumab in People With Rectal Cancer | recruiting | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | recruiting | Phase 1 | 22 | University of California, IrvineOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | suspended | Phase 1 / Phase 2 | 53 | University of ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04130854 | INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | completed | Phase 2 | 58 | University of Texas Southwestern Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04511039 | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | recruiting | Phase 1 | 45 | Roswell Park Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02837263 | PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer | completed | Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07543848 | A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer | not yet recruiting | Phase 2 | 20 | Chongqing University Cancer HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02863107 | Young-Onset Colorectal Cancer | active not recruiting | — | 818 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06569368 | Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02688712 | ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | active not recruiting | Phase 2 | 50 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04624555 | The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors | recruiting | — | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06955767 | Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes(EXOSCOL02) | recruiting | N/A | 650 | CHU de ReimsOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05108428 | Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma | active not recruiting | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04963283 | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | active not recruiting | Phase 2 | 48 | University of Colorado, DenverOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04703101 | Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | recruiting | Phase 1 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 16, 2026source: clinicaltrials